GLP-1, DPP-4 'precancerous' probe expands: EMA joins FDA
This article was originally published in Scrip
Executive Summary
With data now in hand, the European Medicines Agency on 26 March was ready to follow the US FDA in alerting prescribers, patients and the general public that it also was investigating findings by a group of independent academic researchers that suggest an increased risk of pancreatitis and precancerous cellular changes in patients with Type II diabetes treated with glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors.